Indianapolis, IN, United States of America

James Ronald Gillig

This inventor holds 9 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Eli Lilly and Company, Eli Lilly. Active years: 1996-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James Ronald Gillig. Retrieved from https://idiyas.com/inventor/james-ronald-gillig

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 9

% Patents Active = 55.6

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.0

ph-index = 6

Forward Citations = 113(Granted Patents)

Company Filing History:

8 out of 4,517

Eli Lilly and Company

Years Active: 1996-2019

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10253041 - 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors (2019-04-09),

2. 8044090 - N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor (2011-10-25),

3. 7230011 - [object Object] (2007-06-12),

4. 7229987 - Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes (2007-06-12),

5. 7157488 - [object Object] (2007-01-02),

6. 7132456 - MCH receptor antagonists (2006-11-07),

7. 5559228 - Synthesis of bisindolylmaleimides (1996-09-24),

8. 5491242 - Protein kinase C inhibitors (1996-02-13),

9. 5481003 - Protein kinase C inhibitors (1996-01-02),

Title: James Ronald Gillig: A Pioneer in Innovation

Introduction:

James Ronald Gillig, a visionary inventor based in Indianapolis, IN, US, is known for his boundless passion for innovation and his relentless pursuit of pushing technological boundaries. With a total of 9 patents to his name, Gillig has solidified his place as a true pioneer in the world of inventions.

Latest Patents:

Among his latest patents are groundbreaking innovations such as the "7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors." These compounds and formulations showcase Gillig's expertise in developing cutting-edge solutions for complex problems in the field of pharmaceuticals. Additionally, his invention of "N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor" demonstrates his commitment to addressing neurological challenges with innovative solutions.

Career Highlights:

With a remarkable career spanning across renowned companies like Eli Lilly and Company, Gillig has continuously demonstrated his prowess in transforming ideas into tangible inventions. His journey has been marked by a series of breakthroughs that have not only shaped the industry but also paved the way for future innovations.

Collaborations:

Throughout his career, Gillig has collaborated with industry stalwarts like Lawrence Joseph Heinz, II, and Michael R Jirousek. These collaborations have not only enhanced the value of his inventions but also enriched the overall innovation ecosystem.

Conclusion:

In conclusion, James Ronald Gillig stands as a beacon of inspiration for aspiring inventors around the globe. His dedication to pushing the boundaries of technology and his unwavering commitment to innovation continue to inspire generations to dream big, think differently, and create the impossible. Gillig's legacy in the world of inventions is sure to endure for years to come, shaping the future of technology and innovation.

Profile summary based on public USPTO records.